Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3H2101
Thu, 21.12.2023
aap Implantate AG
The Management Board of aap Implantate AG ("aap" or "Company") adjusts the forecast for sales and EBITDA for the financial year 2023. In addition, the Management Board today approved a package of measures for extensive staff reductions and further cost reductions.
The Management Board expects sales of EUR 11.2 million to EUR 11.8 million for the [ … ]
Mon, 30.10.2023
aap Implantate AG
Clinical trial: Visible acceleration with already more than 60 patients recruited since clinical trial resumption in April; completion of patient recruitment planned in 2024
BMBF funding: increase in total funding by around EUR 0.4 million to up to EUR 3.1 million underscores the strategic innovative character of aap's antibacterial silver coat [ … ]
Wed, 04.10.2023
aap Implantate AG
aap Implantate AG ("aap" or the "Company") today completed the placement of the mandatory convertible bond 2023/2028, which the Company's Management Board resolved to issue with the approval of the Supervisory Board on September 8, 2023.
The issue met with a positive response from shareholders and new investors of aap in a capital market environmen [ … ]
Fri, 08.09.2023
aap Implantate AG
The Management Board of aap Implantate AG ("aap" or the "Company") resolved today, with the approval of the Supervisory Board on the same day, to make use of the authorization granted by the Annual General Meeting on June 21, 2022 to issue convertible bonds and to issue a non-subordinated and unsecured mandatory convertible bond 2023/2028 in the to [ … ]
Thu, 31.08.2023
aap Implantate AG
aap Implantate AG ("aap" or the "Company") announces that Mr. Jochen Rahner will succeed CFO Mr. Marek Hahn as Director Finance, IR and IT as of November 1, 2023. Mr. Rahner has over 20 years of financial experience in various functions and holds a degree in mechanical engineering. We are convinced that Mr. Rahner will confidently lead the areas of [ … ]
Mon, 14.08.2023
aap Implantate AG
Sales: Q2 at EUR 2.9 million (+8 % yoy) and H1 at EUR 5.9 million (+6 % yoy); all regions in Q2 above previous year with LATAM (Q2: +13 %; H1: +29 % yoy) and North America (Q2: +7 %; H1: +11 % yoy) as main growth drivers
EBITDA: improvement in Q2 (+21 %) with EUR ‑0.6 million (Q2/2022 corr.: EUR ‑0.7 million) and H1 (+13 %) with EUR ‑1.0 millio [ … ]
Thu, 27.07.2023
aap Implantate AG
aap shareholders met for the Annual General Meeting in Berlin on July 25, 2023
Around 63 percent of the capital stock was represented at the Annual General Meeting
All items on the agenda were approved with approval rates of >99 %
aap Implantate AG ("aap" or the "Company") had invited its shareholders to the Annual General Meeting on July [ … ]
Thu, 27.07.2023
aap Implantate AG
aap shareholders met for the Annual General Meeting in Berlin on July 25, 2023
Around 63 percent of the capital stock was represented at the Annual General Meeting
All items on the agenda were approved with approval rates of >99 %
aap Implantate AG ("aap" or the "Company") had invited its shareholders to the Annual General Meeting on July [ … ]
Fri, 21.07.2023
aap Implantate AG
The Management Board of aap Implantate AG ("aap" or the "Company") today resolved to remove certain agenda items originally proposed for resolution at the Company's forthcoming Annual General Meeting on July 25, 2023 regarding
Reduction of the share capital of the Company from EUR 8,955,849.00 by EUR 6,716,887.00 to EUR 2,238,962.00 (agenda items [ … ]
Fri, 21.07.2023
aap Implantate AG
The Management Board of aap Implantate AG ("aap" or the "Company") today resolved to remove certain agenda items originally proposed for resolution at the Company's forthcoming Annual General Meeting on July 25, 2023 regarding
Reduction of the share capital of the Company from EUR 8,955,849.00 by EUR 6,716,887.00 to EUR 2,238,962.00 (agenda items [ … ]